Braveheart Bio targets up to $318.8M in US IPO

Braveheart Bio, a clinical-stage biopharmaceutical company, has filed for an initial public offering on the Nasdaq Global Market under the ticker symbol NASDAQ: BRVE, according to a press release statement.

The company is offering 18,750,000 shares priced between $15.00 and $17.00 per share, targeting up to $318.8 million in proceeds.

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor are serving as underwriters for the offering.

You May Also Be Interested In

• Accelevation Holdings files for IPO on Nasdaq at $20-$24/sh
• Decoy Therapeutics corrects warrant exercisability in inducement deal
• Beyond Meat ordered to pay $15.4M in trademark infringement case